Terumo Corporation · TSE:4543

Terumo — Investor Day (June 2022)

26 slides from Terumo's investor day presentation, Jun 23, 2022

Slide 2: Table of Contents
Table of Contents  Executive Management Committee Introduction  Strategic Vision and Growth Strategy  Business Overview  Plasma Innovations Ecosystem  Wrap Up ©TERUMO CORPORATION 2
Slide 3: Executive Management Committee
Executive Management Committee We have invested in talent to support our aspirations  Recruited seasoned leaders to create market- driven innovation and unleash enterprise synergies Chetan Makam Veerle d’Haenens Delara Motlagh Cynthia Hougum John Tanner Gene Stellon Blood Center Therapeutic Cell Th
Slide 4: Strategic Vision
Strategic Vision Our Aspiration  Provide compelling and accessible innovations globally that unlock the power of blood and cells to improve patient outcomes and serve unmet medical needs How this will be achieved  By inspiring and engaging our associates, we will optimize quality and deliver world
Slide 5: Returned to Growth – Revenue and Profit
Returned to Growth – Revenue and Profit Historical Operating Performance Transformational Shifts US$ in Millions  Shifted investment to growth areas 4.0%  Diversified beyond equipment and blood 4.7% 4.2% 8.8% 0.2%  Built infrastructure in growth geographies 0.0% $1073 $1032  Sharpened strategic
Slide 6: Met Growth Targets and Continued Our Transformation Despite COVID
Met Growth Targets and Continued Our Transformation Despite COVID Our Commitment 1 Protect Our Associates 2 Serve Customers and Patients 3 Conserve Cash  Safety  Flexed production to serve patient  Prioritized programs to build  Security hot spots contingency  Mental Health  Developed COVID so
Slide 7: Operations Transformation
Operations Transformation Shifting production to build customer delivery flexibility while lowering costs Larne, Ireland • Products: Solutions • Markets: Global/CMO Littleton, US NEW Lakewood, US Fujinomiya, Japan • Products: Plasma • Products: Devices and Disposables • Products: Blood Bags, Filters
Slide 8: Newly Built Costa Rica Facility
Newly Built Costa Rica Facility Bringing the best of our global manufacturing design and processes  Costa Rica is a proven hub for the production of medical devices  World-class facility - increased capacity to serve global markets  Excellent talent and supply chain infrastructure, strategically
Slide 9: Market Dynamics Inform Strategic Choices
Market Dynamics Inform Strategic Choices Market Dynamics Strategic Implications  Donor shortages and shifts  Changing demographics  Increase in chronic disease  Disease & patient data enabling  Data integration expected personalized medicine  Clinical efficacy required  Rationalize portfolio
Slide 10: Aligning Investments with Growth Areas
Aligning Investments with Growth Areas Estimated Growth Rate* Create | Disrupt 20% Whole Blood Cell Therapy Plasma Automation Innovations Focus | Reframe 5% Therapeutic Autologous Apheresis Biologics Optimize 5% Automated Whole Blood Contract Blood Collection Core Manufacturing Safety Legend: = FY21
Slide 11: Shape the Future Across a Diverse Care Continuum
Blood Centers Solutions Shape the Future Across a Diverse Care Continuum Unmet local needs inform unique business models and growth in the core blood business Continuum of Transfusion Therapies ❶ Recruit ❷ Collect ❸ Process ❹ Deliver ❺ Treat Leapfrog in underserved markets Transform Advanced Blood C
Slide 12: Building for the Future
Blood Centers Solutions Building for the Future Equipment and beyond: Areas of exploration and investment Veda Solutions Advancing automation Going beyond devices with Data enables efficiencies as a global standard services and clinical insights and decision-making ©TERUMO CORPORATION 12
Slide 13: Enhancing Access to Therapies That Serve Unmet Medical Needs
Therapeutic Systems Enhancing Access to Therapies That Serve Unmet Medical Needs Improving options in the care journey for sickle cell disease Every year, about 300,000 newborns are diagnosed with sickle cell disease Synergies with drug options Automated Cell and red blood cell gene exchange therapi
Slide 14: Transforming Therapy Options for Patients with Triple-Negative Breast Cancer
Therapeutic Systems Transforming Therapy Options for Patients with Triple-Negative Breast Cancer Collaborations reinforce the diversity and power of the Spectra Optia platform Each year there are over 2 million newly diagnosed breast cancer patients worldwide Immuno- therapies Immuno- Chemotherapy p
Slide 15: Bridging Clinics and Biotechs to Increase Therapy Access
Cell Therapy Technologies Bridging Clinics and Biotechs to Increase Therapy Access Facilitate the journey of life-saving cells from patient collection through the ultimate transfusion Patient Journey Testing and Cell Collection Patient Coordination and Preparation Testing & Collection Center Veda So
Slide 16: Investing to Shape the Cell Therapy Ecosystem
Cell Therapy Technologies Investing to Shape the Cell Therapy Ecosystem Support biotechs with holistic solutions to make innovative therapies accessible to more patients Biotechs CDMOs Global drug developers Cell Collection Cell Manufacturing Service and Data Standardized cell products and Scalable
Slide 17: Unlocking our potential to provide compelling and accessible innovations
Plasma Innovations Pete Atherton Common Variable Immune Deficiency Patient, USA Unlocking our potential to provide  Long journey to diagnosis and lack of access to medicines compelling and accessible innovations  One patient requires multiple donations per year to serve unmet medical needs globall
Slide 18: Innovating in the Source Plasma Market
Innovating in the Source Plasma Market Optimizing the donor experience and operational efficiencies Rika Kinari Plasma Donation System Device Management Platform Integrated Supply Built Ecosystem Myata Chain and Distribution to Meet Unmet Customer Service Portal Market Needs State-of-the-Art Automat
Slide 19: Rika Plasma Donation System
Rika Plasma Donation System An ecosystem designed to advance the plasma market  Designed for the “-abilities”  Focused on usability and donor cycle time  Integrates plasma collection technology, data solutions, services and program support ©TERUMO CORPORATION 19
Slide 20: Innovation Centered in the Donor Experience
Innovation Centered in the Donor Experience Comfort and safety at the core  Donation completed in 35 minutes or less  Intelligent donation – Rika senses the donor  Real-time status of donation progress  No more than 200 mL of blood outside the body at any time  Designed to encourage repeat dona
Slide 21: Positioned to Innovate the Source Plasma Market and Beyond
Positioned to Innovate the Source Plasma Market and Beyond Investment that will inform the next generation of innovation across the businesses Rika Kinari Plasma Donation System Device Management Platform Integrated Supply Built Ecosystem Myata Chain and Distribution to Meet Unmet Customer Service P
Slide 22: Infrastructure to support Plasma Innovations Ecosystem
Infrastructure to support Plasma Innovations Ecosystem  New state-of-the-art factory in Littleton, Colorado State-of-the-Art  Automated assembly, packaging, and quality inspection Automated Manufacturing  Support the ramp of new contract manufacturing  Built production departments at two contrac
Slide 23: Look Out and Forward to Transform our Profit Profile
Look Out and Forward to Transform our Profit Profile Shifting investment to growth programs while improving margins High Profit, High Growth Market Entry Adjusted Operating Profit Aspiration  Plasma Innovations (M USD at FY21 Plan FX Rate FY20-26) Optimize Profit Contribution from Existing ~20% Por
Slide 24: 5-Year Growth Strategy: Terumo Blood and Cell Technologies
5-Year Growth Strategy: Terumo Blood and Cell Technologies Strategic investments transform our portfolio and profit potential Blood and Equipment Geographic Operational Beyond and Beyond Expansion Excellence  Transform the source  Differentiate with  Bring safe blood  Optimized global plasma ind
Slide 25: Unlocking our Potential to Serve More Patients
Unlocking our Potential to Serve More Patients Multiple Myeloma Sickle Cell Disease Acute Lymphoblastic Leukemia Common Variable Immune Deficiency ©TERUMO CORPORATION 25

Terumo — Investor Day (June 2022) on 6ix

Terumo — Investor Day (June 2022)

Slide 1: Welcome to Investors' Day

Slide 2: Table of Contents

Slide 3: Executive Management Committee

Slide 4: Strategic Vision

Slide 5: Returned to Growth – Revenue and Profit

Slide 6: Met Growth Targets and Continued Our Transformation Despite COVID

Slide 7: Operations Transformation

Slide 8: Newly Built Costa Rica Facility

Slide 9: Market Dynamics Inform Strategic Choices

Slide 10: Aligning Investments with Growth Areas

Slide 11: Shape the Future Across a Diverse Care Continuum

Slide 12: Building for the Future

Slide 13: Enhancing Access to Therapies That Serve Unmet Medical Needs

Slide 14: Transforming Therapy Options for Patients with Triple-Negative Breast Cancer

Slide 15: Bridging Clinics and Biotechs to Increase Therapy Access

Slide 16: Investing to Shape the Cell Therapy Ecosystem

Slide 17: Unlocking our potential to provide compelling and accessible innovations

Slide 18: Innovating in the Source Plasma Market

Slide 19: Rika Plasma Donation System

Slide 20: Innovation Centered in the Donor Experience

Slide 21: Positioned to Innovate the Source Plasma Market and Beyond

Slide 22: Infrastructure to support Plasma Innovations Ecosystem

Slide 23: Look Out and Forward to Transform our Profit Profile

Slide 24: 5-Year Growth Strategy: Terumo Blood and Cell Technologies

Slide 25: Unlocking our Potential to Serve More Patients

Slide 26: ©TERUMO CORPORATION